Immunovia Takes Action During COVID-19 Pandemic and Remains Focused on Launch of IMMray[™] PanCan-d
LUND, SWEDEN – Immunovia AB (publ) (“Immunovia”) today provides an update on the actions that the company is taking to support patients, employees, and public health initiatives in response to the coronavirus (COVID-19) pandemic. Despite these extraordinary times, Immunovia remains focused on the Q3 2020 sales start for the first test for early diagnosis of pancreatic cancer, IMMray™ PanCan-d. The company will continue to monitor the global development of the COVID-19 epidemic closely and enact strategies that adhere to authorities' guidelines in each of the countries where we are active